Arcus Biosciences (RCUS) Free Cash Flow (2017 - 2026)

Arcus Biosciences has reported Free Cash Flow for 10 years, with the latest figure at -$138.0 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 3.76% year-over-year to -$138.0 million; the trailing twelve-month figure through Mar 2026 stood at -$487.0 million (down 59.15% YoY), and the FY2025 full-year result was -$482.0 million, down 173.86% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$138.0 million, down from -$119.0 million in the prior quarter.
• The five-year high for Free Cash Flow was $653.0 million in Q1 2022, with the low at -$138.0 million in Q1 2026.
• Average Free Cash Flow over 5 years is -$39.5 million, with a median of -$83.0 million recorded in 2022.
• Year-over-year, Free Cash Flow jumped 1045.01% in 2022 and sank 4333.33% in 2025.
• Tracing RCUS's Free Cash Flow over 5 years: stood at -$70.0 million in 2022, then fell by 2.86% to -$72.0 million in 2023, then sank by 40.28% to -$101.0 million in 2024, then decreased by 17.82% to -$119.0 million in 2025, then declined by 15.97% to -$138.0 million in 2026.
• The last three Free Cash Flow figures came in at -$138.0 million (Q1 2026), -$119.0 million (Q4 2025), and -$97.0 million (Q3 2025), per Business Quant data.

Peer Comparison